在KMT2A重组急性白血病的最新发展和不断发展的治疗策略
Lei Yin1, Lin Wan2, Youjian Zhang1
1Department of Clinical Laboratory, Children's Hospital of Soochow University, Suzhou, China.
Cancer medicine
|October 21, 2024
概括
在急性白血病中,KMT2A重组很常见,导致侵袭性疾病和不良结果. 研究重点是个性化疗法和免疫疗法,以改善患者的预后和生活质量.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 在急性髓性白血病 (AML) 和急性淋巴细胞白血病 (ALL) 中,KMT2A重组 (KMT2A-r) 是常见的.
- KMT2A-r白血病呈侵袭性,预后不佳,往往对化学疗法和HSCT等当前治疗的反应有限.
- 这些重组在婴儿白血病,二次白血病和显著的成年AML百分比中特别普遍.
研究的目的:
- 审查KMT2A-r急性白血病,涵盖基因特征,机制和临床方面.
- 研究KMT2A-rAML和ALL的细胞遗传学,免疫类型,临床表现和风险分层.
- 专门研究KMT2A-r急性白血病的当前和新兴治疗目标.
主要方法:
- 使用PubMed.com进行系统的文献审查.
- 关键词包括"KMT2A重组的急性白血病"",淋巴细胞白血病"",骨髓性白血病"和"治疗".
- 研究是根据质量和相关性进行选择的.
主要成果:
- 在白血病中,KMT2A重组是一个关键问题,在70%以上的婴儿病例和约10%的成年AML中发现.
- 该综述整合了关于KMT2A-r白血病的生物学,临床特征和治疗前景的信息.
- 确定治疗目标和治疗策略对于管理这种侵袭性疾病至关重要.
结论:
- 未来的研究强调针对KMT2A-r急性白血病的个性化疗法,免疫疗法和基因组进展.
- 创新的治疗组合和正在进行的临床试验为改善患者治疗结果提供了希望.
- 其目标是提高治疗效率,减少疾病负担,改善受影响个人的生活质量.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)